Clinical Trials
19 trialsNCT07605416 2026-05-26
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT06948084 2026-05-13
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07513129 2026-04-21
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07221032 2026-04-14
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07485647 2026-03-20
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Vanderbilt-Ingram Cancer Center
Phase 2 Not yet recruiting
NCT07393282 2026-03-16
LINKER-SMM2
Regeneron Pharmaceuticals
Phase 3 Not yet recruiting
NCT07029776 2026-03-03
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas
Phase 2 Not yet recruiting
NCT07428369 2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT07400744 2026-02-10
A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
Qilu Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07335887 2026-01-13
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT07072585 2025-12-31
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)
Children's Oncology Group
Phase 2/3 Not yet recruiting
NCT07247097 2025-11-25
ELDORADO
Massachusetts General Hospital
Phase 2 Not yet recruiting
NCT07090954 2025-07-29
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07026604 2025-06-18
CCM-DS01
Beijing Tiantan Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT07015021 2025-06-11
DKPD
The First Affiliated Hospital of Soochow University
Phase NA Not yet recruiting
NCT06931704 2025-04-23
IFM 2024_06
Nantes University Hospital
Phase 2 Not yet recruiting
NCT05581875 2022-10-17
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory
Hellenic Society of Hematology
Phase 1/2 Not yet recruiting
NCT05054478 2021-09-23
PCL-2
Assistance Publique - Hôpitaux de Paris
Phase 2 Not yet recruiting